caa a22 4500 477061737 CHVBK 20180405111402.0 cr unu---uuuuu 170330e19960301xx s 000 0 eng 10.1007/BF00226412 doi (NATIONALLICENCE)springer-10.1007/BF00226412 Comparison of N-glycan pattern of recombinant human coagulation factors II and IX expressed in Chinese hamster ovary (CHO) and African green monkey (Vero) cells [Elektronische Daten] [Bernhard Fischer, Artur Mitterer, Friedrich Dorner, Johann Eibl] The N-glycan patterns of recombinant human coagulation factors II (rF-II) and IX (rF-IX), derived from both transfected Chinese hamster ovary (CHO) cells and African green monkay (Vero) cells produced at industrial scale, were analyzed by binding to carbohydrate-specific lectins and were compared with the glycan structure of human plasma-derived coagulation factors. Human plasma-derived coagulation factors II (hpF-II) and IX (hpF-IX) exhibited complex-type glycan structures with carbohydrate chains capped with α(2-6)-sialic acid. Terminal galactose-β(1-4)-N-acetylglucosamine units were detected in hpF-IX. Both CHO cell-derived rF-II and rF-IX exhibited complex-type glycosylation and contained α(2-3)-sialic acid in addition to terminal galactose-β(1-4)-N-acetylglucosamine. Vero cell-derived rF-IX exhibited a complex-type glycan structure similar to that of CHO cell-derived rF-IX. In contrast, rF-II produced by Vero cells exhibited a glycan microheterogeneity composed of hybrid-type glycosylation containing "high-mannose” structures and complex-type glycosylation containing α(2-3)-sialic acid. Galactose-β(1-4)-N-acetylglucosamine structures and a low concentration of α(2-6)-sialic acid were detected in both microheterogeneity fractions of Vero cell-derived rF-II. Although different in their carbohydrate structures, coagulation factors II and IX obtained recombinantly from both transformed CHO cells and Vero cells exhibited coagulation activities comparable with the plasma-derived proteins. Kluwer Academic Publishers, 1996 coagulation factor nationallicence recombinant nationallicence glycosylation nationallicence Fischer Bernhard IMMUNO AG, Biomedical Research Center, Orth/Donau, Austria aut Mitterer Artur IMMUNO AG, Biomedical Research Center, Orth/Donau, Austria aut Dorner Friedrich IMMUNO AG, Biomedical Research Center, Orth/Donau, Austria aut Eibl Johann IMMUNO AG, Biomedical Research Center, Orth/Donau, Austria aut Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 3/1(1996-03-01), 57-62 0929-5305 3:1<57 1996 3 11239 https://doi.org/10.1007/BF00226412 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00226412 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Fischer Bernhard IMMUNO AG, Biomedical Research Center, Orth/Donau, Austria aut NATIONALLICENCE 700 1- Mitterer Artur IMMUNO AG, Biomedical Research Center, Orth/Donau, Austria aut NATIONALLICENCE 700 1- Dorner Friedrich IMMUNO AG, Biomedical Research Center, Orth/Donau, Austria aut NATIONALLICENCE 700 1- Eibl Johann IMMUNO AG, Biomedical Research Center, Orth/Donau, Austria aut NATIONALLICENCE 773 0- Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 3/1(1996-03-01), 57-62 0929-5305 3:1<57 1996 3 11239 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer